Shifeng Lou

ORCID: 0000-0003-1621-1171
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • Acute Myeloid Leukemia Research
  • Hemophilia Treatment and Research
  • Blood Coagulation and Thrombosis Mechanisms
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Hematopoietic Stem Cell Transplantation
  • CAR-T cell therapy research
  • RNA Interference and Gene Delivery
  • Hematological disorders and diagnostics
  • Immune Cell Function and Interaction
  • Cancer Research and Treatments
  • Healthcare and Venom Research
  • Viral-associated cancers and disorders
  • T-cell and Retrovirus Studies
  • Autoimmune and Inflammatory Disorders Research
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer, Hypoxia, and Metabolism
  • Lysosomal Storage Disorders Research
  • Diet and metabolism studies
  • Parvovirus B19 Infection Studies
  • Neutropenia and Cancer Infections
  • Mycobacterium research and diagnosis
  • Molecular Biology Techniques and Applications
  • Beetle Biology and Toxicology Studies
  • Ultrasound Imaging and Elastography

Second Affiliated Hospital of Chongqing Medical University
2009-2025

Dalian Medical University
2009-2025

Chongqing Medical University
2010-2025

Chongqing University
2008

Second Military Medical University
2003

Background Congenital factor VII (FVII) deficiency is a genetic disorder characterized by decreased FVII activity, which sometimes leads to fatal bleeding. Numerous variants have been found in deficiency, but mutations vary among patients. Each mutation deserves further exploration for each patient at risk of We previously reported Chinese with p.L68R∗37 and p.T241N compound heterozygous mutations. In this study, we investigated the impact these two on expression through vitro experiments....

10.1097/mbc.0000000000001340 article EN Blood Coagulation & Fibrinolysis 2025-01-06

To investigate the feasibility of using focused ultrasound (FUS) with microbubbles for targeted delivery cytarabine to brain. Sprague–Dawly rats (weighing 200–250 g) received intravenous injection microbubbles. At 0, 2, 4, 8, and 24 hours (n = 5 each time point) after sonication, animals administration at a normal dose 4 mg/kg body weight. Additional five were given high (50 weight) alone. Blood–brain barrier (BBB) permeability cerebral determined. FUS in conjunction caused transient BBB...

10.1179/1973947812y.0000000043 article EN Journal of Chemotherapy 2012-12-01

Glucocorticoids (GCs) are routinely believed to work solely through genomic mechanisms. Recent evidence indicates that GCs can act at the membrane exert rapid nongenomic effects on various tissues and cells. To ascertain whether of exist allergic asthma reaction, Hartley guinea pigs were sensitized with ovalbumin challenged same antigen given by aerosol. Some animals received inhaled budesonide (3 mg/ml suspended in Hydroxypropyl methylcellulose vehicle) for 5 minutes before challenge; Other...

10.1677/joe.0.177r001 article EN Journal of Endocrinology 2003-04-01

T-cell lymphoblastic lymphoma (T-LBL) is a highly aggressive form of with poor clinical outcomes and lacks standard treatment regimen. In this study, we assessed the safety efficacy tandem autologous hematopoietic stem cell transplantation (auto-HSCT) strategy for adult T-LBL evaluated prognostic factors affecting survival. 181 Newly-diagnosed patients were enrolled, 89 treated chemotherapy alone, 46 allocated to single auto-HSCT group, auto-HSCT. The median follow-up time was 37 months,...

10.3324/haematol.2019.226985 article EN cc-by-nc Haematologica 2019-11-28

Plasmablastic lymphoma (PBL) is a rare and recently described entity of large B-cell lymphoma. It predominantly occurs in the oral cavity human immunodeficiency virus (HIV)-positive patients exhibits highly aggressive clinical behavior without effective treatment. Recently, sporadic cases describing PBL extraoral locations HIV-negative have been reported; frequently with underlying immunosuppressive states. To develop understanding PBL, current study reports unusual presentation duodenal...

10.3892/ol.2014.2604 article EN Oncology Letters 2014-10-10

Abstract Introduction Current treatment of severe haemophilia A includes prophylaxis with factor VIII (FVIII) replacement. The supply plasma‐derived FVIII is short in China. Purpose To evaluate the efficacy and safety a new B‐domain deleted (BDD) recombinant (TQG202) produced by human‐derived cells for patients compare bioequivalence Xyntha. Methods This multicentre, clinical trial consisted an open‐label, randomized, two‐period cross‐over assessing single‐dose pharmacokinetics (PK),...

10.1111/hae.14652 article EN cc-by-nc-nd Haemophilia 2022-08-22
Coming Soon ...